|Bid||2.4600 x N/A|
|Ask||2.4700 x N/A|
|Day's Range||2.3200 - 2.4900|
|52 Week Range||1.5400 - 10.2100|
|Beta (5Y Monthly)||1.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul. 13, 2020 - Jul. 17, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.54|
A pair of marijuana stocks, Tilray (NASDAQ: TLRY) and OrganiGram Holdings (NASDAQ: OGI), both dropped notably in price on Friday (by 5.2% and 7%, respectively). The culprit seems to be another weed title, Canopy Growth (NYSE: CGC), which earlier in the day published an awful quarterly earnings release. Canopy Growth is a leading company in the sector.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (collectively, the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that the Company has amended its credit agreement dated May 31, 2019, with Bank of Montreal ("BMO") as lead arranger and agent as well as a syndicate including three other lenders (the "Credit Agreement Amendment"). The Credit Agreement Amendment modifies certain terms of the $115 million term loan (the "Term Loan") and $25 million revolving credit facility (the "Revolver", and together with the Term Loan, the "Facilities").
Shares of Organigram Holdings (NASDAQ: OGI) were flying on Thursday after the company said it was rolling out its "cannabis 2.0" products to its medical marijuana customers. As of 3:27 p.m. EDT, Organigram's stock was up more than 12%. Cannabis 2.0 is a term used to describe second-generation marijuana products such as edibles and beverages, as opposed to cannabis 1.0 products like dried flower.
Vapes and chocolate edibles are among the new cannabis products the company is rolling out to medical marijuana consumers.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce that as of May 19th, 2020, the Company has extended its medical cannabis offering to include products from its cannabis 2.0 adult-use recreational portfolio.
No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.
Shares of Aurora Cannabis (NYSE: ACB) sank on Wednesday after analysts raised concerns that the popular marijuana stock's price gains may have come too far, too fast. As of 3 p.m. EDT, Aurora's stock was down more than 12%. Aurora's shares surged as much as 180% following the cannabis producer's better-than-expected third-quarter sales results on May 14.
If you're looking to invest in the cannabis industry, you have to be prepared to take on some significant risks. The industry's been struggling during the past year, and a turnaround is not necessarily imminent. This year is already setting up to be a challenging one for many pot stocks, and investors should be careful not to be lured in by low prices.
Shares of several top Canadian cannabis producers soared today after one of their peers, Aurora Cannabis (NYSE: ACB), reported better-than-expected fiscal 2020 third-quarter revenue growth after the market closed on Thursday. Canopy Growth (NYSE: CGC) stock was up 13.4% as of 3:38 p.m. EDT on Friday, while shares of Cronos Group (NASDAQ: CRON) and OrganiGram Holdings (NASDAQ: OGI) were up 10.3% and 13.5%, respectively. Investors now appear to be increasingly optimistic that the rest of the Canadian cannabis industry could also enjoy a turn for the better after a challenging period following Aurora's surprisingly positive results.
As it continues to monitor and assess the implications of the COVID-19 pandemic, Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, has announced the first phase of its return-to-work strategy. The Company has begun to implement a staggered return-to-work plan effective May 13, 2020.
MONCTON, New Brunswick--(BUSINESS WIRE)--The Nova Scotia Court of Appeal has partially overturned the certification of a class action (the “Class Action”) against Organigram Inc. (the "Company" or "Organigram") and its parent company Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis in Canada, on April 30, 2020 thereby significantly reducing the scope of the claim against the Company.
Even after its disastrous second-quarter results and subsequent price drop, I'm sold on this cannabis company's COVID-19 strategies and its approach to cannabis 2.0.
With the global economy withering under the COVID-19 pandemic, the odds of a wave of bankruptcies wiping out underperforming cannabis firms are on the rise.
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to provide an update related to the Company’s current and anticipated releases of new adult use recreational cannabis products.
Organigram Holdings Inc. ("Organigram" or the "Corporation") (TSX:OGI) (NASDAQ:OGI) announced today that it has established an at-the-market equity program (the "ATM Program") that allows the Corporation to issue up to C$49,000,000 (or its U.S. dollar equivalent) of common shares ("Common Shares") from treasury to the public from time to time, at the Corporation’s discretion. Any Common Shares sold in the ATM Program will be sold through the Toronto Stock Exchange (the "TSX"), the NASDAQ Global Select Market (the "NASDAQ") or any other marketplace on which the Common Shares are listed, quoted or otherwise traded, at the prevailing market price at the time of sale.
Quarterly profits are a rarity in the Canadian cannabis sector, but two large pot companies surprised investors with strong financial results.
When the approximately 400 Organigram workers laid off in response to COVID-19 will be allowed to return to their jobs will depend in part on “growth in the market,” according to the cannabis producer’s chief executive officer.
OrganiGram (OGI) delivered earnings and revenue surprises of -100.00% and -15.60%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce its results for the second quarter ended February 29, 2020 ("Q2" or "Q2 2020").